Ligand validation:6SE9

GAL: beta-D-galactopyranose

GAL is a Ligand Of Interest in 6SE9 designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6SE9_GAL_A_1110	1%	65%	0.349	0.488	0.53	0.8	-	-	0	0	100%	1
6ZJS_GAL_A_1101	92%	66%	0.069	0.961	0.55	0.74	-	-	0	0	100%	1
6ZJQ_GAL_A_1107	87%	62%	0.079	0.952	0.71	0.75	-	-	1	0	100%	1
6SEA_GAL_A_1112	27%	49%	0.204	0.85	0.87	1.08	-	1	0	0	100%	0.7
6ZJW_GAL_A_1101	7%	74%	0.259	0.719	0.37	0.62	-	-	1	0	100%	0.8
6ZJT_GAL_A_1104	6%	53%	0.324	0.767	0.91	0.91	-	1	0	0	100%	1
4WWH_GAL_B_401	100%	61%	0.027	0.99	0.5	0.97	-	1	0	0	100%	1
5ELB_GAL_C_202	100%	58%	0.036	0.992	0.82	0.8	-	-	0	0	100%	0.6
3OGR_GAL_A_1024	99%	47%	0.053	0.987	0.79	1.26	-	1	1	0	100%	1
1NSX_GAL_B_2400	98%	50%	0.055	0.981	0.56	1.36	-	3	0	0	100%	1
5DVJ_GAL_B_501	98%	40%	0.047	0.968	0.95	1.38	-	3	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.